drugset / Trial / NCT04685564
A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a single dose-escalation phase Ⅰa clinical study to observe the safety and pharmacokinetic profiles of RBD1016 in healthy subjects. The study consists of screening period (Day -28 to Day -1), treatment period (Day 1 to Day 2), safety assessment period (to Day 29) and safety follow-up period (up to Day 85).
Timeline
- Start
- 2021-02-05
- Primary completion
- 2021-09-08
- Completion
- 2021-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBD1016 | Unknown | 0.3 mg/kg | Subcutaneous |
Indications
No indication recorded.